The controlled release of tilmicosin from silica nanoparticles

被引:7
作者
Song, Meirong [1 ]
Li, Yanyan [2 ]
Fai, Cailing [1 ]
Cui, Shumin [1 ]
Cui, Baoan [1 ]
机构
[1] Henan Agr Univ, Coll Sci, Zhengzhou 450002, Peoples R China
[2] Henan Inst Sci & Technol, Dept Educ, Xinxiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Silica nanoparticles; tilmicosin; controlled release; diffusion; nanomaterials; IN-VITRO RELEASE; MESOPOROUS SILICA; DRUG-DELIVERY; CARRIERS; PHARMACOKINETICS; KINETICS; MICOTIL; SERUM;
D O I
10.3109/03639045.2010.538059
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aim of this study was to use silica nanoparticles as the carrier for controlled release of tilmicosin. Tilmicosin was selected as a drug model molecule because it has a lengthy elimination half-life and a high concentration in milk after subcutaneous administration. Three samples of tilmicosin-loaded silica nanoparticles were prepared with different drug-loading weight. The drug-loading weight in three samples, as measured by thermal gravimetric analysis, was 29%, 42%, and 64%, respectively. With increased drug-loading weight, the average diameter of the drug-loaded silica nanoparticles was increased from 13.4 to 25.7 nm, and the zeta potential changed from-30.62 to-6.78 mV, indicating that the stability of the drug-loaded particles in the aqueous solution decreases as drug-loading weight increases. In vitro release studies in phosphate-buffered saline showed the sample with 29% drug loading had a slow and sustained drug release, reaching 44% after 72 h. The release rate rose with increased drug-loading weight; therefore, the release of tilmicosin from silica nanoparticles was well-controlled by adjusting the drug loading. Finally, kinetics analysis suggested that drug released from silica nanoparticles was mainly a diffusion-controlled process.
引用
收藏
页码:714 / 718
页数:5
相关论文
共 25 条
[1]  
BRANKA R, 2010, DRUG DEV IND PHARM, V36, P852
[2]   A preliminary investigation of the disposition of tilmicosin residues in elk tissues and serum [J].
Clark, C ;
Woodbury, M ;
Dowling, P ;
Ross, S ;
Boison, JO .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2004, 27 (05) :385-387
[3]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[4]   Hydrophilic silica aerogels as dermal drug delivery systems - Dithranol as a model drug [J].
Guenther, U. ;
Smirnova, I. ;
Neubert, R. H. H. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 69 (03) :935-942
[5]   Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies [J].
Han, C. ;
Qi, C. M. ;
Zhao, B. K. ;
Cao, J. ;
Xie, S. Y. ;
Wang, S. L. ;
Zhou, W. Z. .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2009, 32 (02) :116-123
[6]  
JORDAN WH, 1993, VET HUM TOXICOL, V35, P151
[7]   Periodic mesoporous silica and organosilica with controlled morphologies as carriers for drug release [J].
Lin, Chun Xiang ;
Qiao, Shi Zhang ;
Yu, Cheng Zhong ;
Ismadji, Suryadi ;
Lu, Gao Qing .
MICROPOROUS AND MESOPOROUS MATERIALS, 2009, 117 (1-2) :213-219
[8]  
MANJA A, 1999, DRUG DEV IND PHARM, V25, P955
[9]  
MANUEL D, J ANTIBIOT, V62, P1253
[10]  
MCGUIGAN MA, 1994, VET HUM TOXICOL, V36, P306